MX2019009846A - Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal. - Google Patents

Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal.

Info

Publication number
MX2019009846A
MX2019009846A MX2019009846A MX2019009846A MX2019009846A MX 2019009846 A MX2019009846 A MX 2019009846A MX 2019009846 A MX2019009846 A MX 2019009846A MX 2019009846 A MX2019009846 A MX 2019009846A MX 2019009846 A MX2019009846 A MX 2019009846A
Authority
MX
Mexico
Prior art keywords
treatment
sulfatase
cognitive impairment
iduronate
hunter syndrome
Prior art date
Application number
MX2019009846A
Other languages
English (en)
Inventor
Mccauley Thomas
Barbier Ann
W Richard Charles Iii
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2019009846A publication Critical patent/MX2019009846A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un método para tratar el deterioro cognitivo del síndrome de Hunter; entre otras cosas, la presente invención proporciona un método que comprende una etapa de administrar intratecalmente a un sujeto que necesita el tratamiento, una enzima iduronato- 2-sulfatasa (I2S) recombinante a una dosis terapéuticamente efectiva y a un intervalo de administración por un período de tratamiento suficiente para mejorar, estabilizar o reducir la disminución de una o más funciones cognitivas, adaptativas, motoras y/o ejecutivas, en relación con un control.
MX2019009846A 2011-12-23 2014-06-20 Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal. MX2019009846A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161580027P 2011-12-23 2011-12-23
US201261590804P 2012-01-25 2012-01-25
US201261590797P 2012-01-25 2012-01-25
US201261609173P 2012-03-09 2012-03-09
US201261734365P 2012-12-06 2012-12-06

Publications (1)

Publication Number Publication Date
MX2019009846A true MX2019009846A (es) 2019-10-14

Family

ID=48669720

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007642A MX367395B (es) 2011-12-23 2012-12-21 Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del síndrome de hunter mediante suministro intratecal.
MX2019009846A MX2019009846A (es) 2011-12-23 2014-06-20 Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014007642A MX367395B (es) 2011-12-23 2012-12-21 Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del síndrome de hunter mediante suministro intratecal.

Country Status (9)

Country Link
US (3) US9682129B2 (es)
EP (1) EP2793933B1 (es)
AU (1) AU2012358223B2 (es)
BR (1) BR112014015352A8 (es)
CA (1) CA2859988A1 (es)
EA (1) EA201792099A1 (es)
ES (1) ES2728447T3 (es)
MX (2) MX367395B (es)
WO (1) WO2013096912A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728447T3 (es) * 2011-12-23 2019-10-24 Shire Human Genetic Therapies Tratamiento del déficit cognitivo del síndrome de Hunter para la administración intratecal de iduronato-2-sulfatasa
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
PE20181329A1 (es) 2015-12-30 2018-08-20 Green Cross Corp Metodos y composiciones para el tratamiento del sindrome de hunter
EP3692070A1 (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
WO2004055157A2 (en) 2002-08-13 2004-07-01 Whitley Chester B Methods of using vectors to treat metabolic disorders
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
IL291554B2 (en) * 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
DK3103469T3 (en) * 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
ES2728447T3 (es) 2011-12-23 2019-10-24 Shire Human Genetic Therapies Tratamiento del déficit cognitivo del síndrome de Hunter para la administración intratecal de iduronato-2-sulfatasa

Also Published As

Publication number Publication date
AU2012358223B2 (en) 2018-01-18
WO2013096912A2 (en) 2013-06-27
EP2793933B1 (en) 2019-04-17
US9682129B2 (en) 2017-06-20
US20180071371A1 (en) 2018-03-15
EP2793933A2 (en) 2014-10-29
MX2014007642A (es) 2015-03-19
MX367395B (es) 2019-08-20
BR112014015352A2 (pt) 2017-06-13
US10568941B2 (en) 2020-02-25
BR112014015352A8 (pt) 2017-06-13
EP2793933A4 (en) 2016-06-08
EA201792099A1 (ru) 2018-05-31
ES2728447T3 (es) 2019-10-24
US20150328289A1 (en) 2015-11-19
AU2012358223A1 (en) 2014-07-03
WO2013096912A3 (en) 2015-06-18
US11357832B2 (en) 2022-06-14
CA2859988A1 (en) 2013-06-27
US20200376093A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
EA201590880A1 (ru) Композиции и способы лечения протеинопатий
AU2018253546A1 (en) Aromatic-cationic peptides and methods for using same
GB2491327A (en) Delayed prolonged drug delivery
MX2019009437A (es) Tratamiento de mielosupresion.
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
GB2491328A (en) Immediate/delayed drug delivery
PH12014501491A1 (en) Subcutaneous therapeutic use of dpp-4 inhibitor
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
MX2014011836A (es) Administracion subcutanea de iduronato-2-sulfatasa.
MX2019009846A (es) Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal.
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
CA2881554C (en) Methods for inhibiting fascin
DK2714888T3 (da) Rekombinant gær
IN2014DN08199A (es)
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2013057592A3 (en) Treatment of sickle cell disease
NZ596780A (en) Immunoregulatory peptides and methods of use
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
MX2021001394A (es) Metodo para mejorar la eficacia de un agente anticanceroso.
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
EA201491047A1 (ru) Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.